(VIANEWS) - Advent Claymore Convertible Securities and Income Fund (AVK), San Juan Basin Royalty Trust (SJT), Putnam Master Intermediate Income Trust (PIM) are the highest dividend yield stocks on this list.
| Rank | Financial Asset | Price | Change | Forward Dividend Yield | Updated (EST) |
|---|---|---|---|---|---|
| 1 | Advent Claymore Convertible Securities and Income Fund (AVK) | 19.37 | 0.05% | 7.26% | 2021-07-03 18:14:06 |
| 2 | San Juan Basin Royalty Trust (SJT) | 4.98 | -3.49% | 7.18% | 2021-07-04 21:42:27 |
| 3 | Putnam Master Intermediate Income Trust (PIM) | 4.20 | 0% | 6.29% | 2021-07-04 18:12:05 |
| 4 | PIMCO California Municipal Income Fund (PCQ) | 19.11 | 0.16% | 4.09% | 2021-07-04 17:45:25 |
| 5 | Pfizer (PFE) | 39.04 | -0.79% | 3.98% | 2021-07-08 10:54:36 |
| 6 | Brookfield Infrastructure Partners LP Limited Partnership Units (BIP) | 56.09 | -0.71% | 3.78% | 2021-07-03 19:45:22 |
| 7 | iStar Financial (STAR) | 20.68 | 0.73% | 2.44% | 2021-07-04 22:26:13 |
Almost 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. Advent Claymore Convertible Securities and Income Fund (AVK) - Dividend Yield: 7.26%
Advent Claymore Convertible Securities and Income Fund is a closed-ended fixed income mutual fund launched and managed by Advent Capital Management, LLC. The fund primarily invests in the fixed income markets of the United States. It seeks to invest in securities of companies operating across the diversified sectors. The fund invests approximately 60% of its portfolio in convertible securities and rest in lower-grade non-convertible income securities. It employs fundamental analysis to create its portfolio. Advent Claymore Convertible Securities and Income Fund was formed on April 29, 2003 and is domiciled in the United States.
Volume
Today's last reported volume for Advent Claymore Convertible Securities and Income Fund is 77464, 37.79% below its average volume of 124523.
Advent Claymore Convertible Securities and Income Fund's last close was $18.41, 6.93% below its 52-week high of $19.78.
Advent Claymore Convertible Securities and Income Fund's Revenue
Year-on-year quarterly revenue growth declined by 21.5%, now sitting on 32.91M for the twelve trailing months.
Advent Claymore Convertible Securities and Income Fund's Stock Yearly Top and Bottom Value
Advent Claymore Convertible Securities and Income Fund's stock is valued at $19.37 at 12:15 EST, below its 52-week high of $19.78 and way higher than its 52-week low of $13.18.
Advent Claymore Convertible Securities and Income Fund's Moving Average
Advent Claymore Convertible Securities and Income Fund's worth is higher than its 50-day moving average of $19.10 and above its 200-day moving average of $17.84.More news about Advent Claymore Convertible Securities and Income Fund.
2. San Juan Basin Royalty Trust (SJT) - Dividend Yield: 7.18%
San Juan Basin Royalty Trust operates as an express trust in Texas. The company has a 75% net overriding royalty interest carved out of Southland's oil and natural gas interests (the subject interests) in properties located in the San Juan Basin in northwestern New Mexico. The subject interests consist of working interests, royalty interests, overriding royalty interests, and other contractual rights in 119,000 net producing acres in San Juan, Rio Arriba, and Sandoval Counties of northwestern New Mexico, as well as 826.3 net wells. BBVA USA serves as the trustee of the San Juan Basin Royalty Trust. The company was founded in 1980 and is based in Houston, Texas.
Volume
Today's last reported volume for San Juan Basin Royalty Trust is 304329, 32.85% above its average volume of 229082.
San Juan Basin Royalty Trust's last close was $5.57, 9.28% below its 52-week high of $6.14.
San Juan Basin Royalty Trust's Revenue
Year-on-year quarterly revenue growth grew by 61.9%, now sitting on 11.99M for the twelve trailing months.
San Juan Basin Royalty Trust's Stock Yearly Top and Bottom Value
San Juan Basin Royalty Trust's stock is valued at $4.98 at 12:15 EST, way below its 52-week high of $6.14 and way above its 52-week low of $2.16.
San Juan Basin Royalty Trust's Moving Average
San Juan Basin Royalty Trust's worth is under its 50-day moving average of $5.38 and way higher than its 200-day moving average of $4.27.More news about San Juan Basin Royalty Trust.
3. Putnam Master Intermediate Income Trust (PIM) - Dividend Yield: 6.29%
Putnam Master Intermediate Income Trust is a closed ended fixed income mutual fund launched and managed by Putnam Investment Management, LLC. The fund is co-managed by Putnam Investments Limited. It invests in the fixed income markets of the United States. The fund invests in bonds of companies operating across diversified sectors. It benchmarks the performance of its portfolio against the Barclays Capital Government/Credit Bond Index. Putnam Master Intermediate Income Trust was formed on April 29, 1988 and is domiciled in the United States.
Volume
Today's last reported volume for Putnam Master Intermediate Income Trust is 110488, 11.7% below its average volume of 125132.
Putnam Master Intermediate Income Trust's last close was $4.21, 5.82% below its 52-week high of $4.47.
Putnam Master Intermediate Income Trust's Revenue
Year-on-year quarterly revenue growth declined by 7.3%, now sitting on 11.2M for the twelve trailing months.
Putnam Master Intermediate Income Trust's Stock Yearly Top and Bottom Value
Putnam Master Intermediate Income Trust's stock is valued at $4.20 at 12:15 EST, below its 52-week high of $4.47 and above its 52-week low of $4.00.
Putnam Master Intermediate Income Trust's Moving Average
Putnam Master Intermediate Income Trust's value is under its 50-day moving average of $4.23 and below its 200-day moving average of $4.22.More news about Putnam Master Intermediate Income Trust.
4. PIMCO California Municipal Income Fund (PCQ) - Dividend Yield: 4.09%
PIMCO California Municipal Income Fund is a closed ended fixed income mutual fund launched and managed by Allianz Global Investors Fund Management LLC. It is co-managed by Pacific Investment Management Company LLC. The fund invests in fixed income markets of the United States. It seeks to invest in stocks of companies operating across diversified sectors. The fund primarily invests in municipal bonds. PIMCO California Municipal Income Fund was formed on June 29, 2001 and is domiciled in New York.
Volume
Today's last reported volume for PIMCO California Municipal Income Fund is 14064, 15.05% below its average volume of 16555.
PIMCO California Municipal Income Fund's last close was $18.47, 3.4% below its 52-week high of $19.12.
PIMCO California Municipal Income Fund's Revenue
Year-on-year quarterly revenue growth declined by 9.6%, now sitting on 18.3M for the twelve trailing months.
PIMCO California Municipal Income Fund's Stock Yearly Top and Bottom Value
PIMCO California Municipal Income Fund's stock is valued at $19.11 at 12:15 EST, below its 52-week high of $19.12 and way higher than its 52-week low of $15.86.
PIMCO California Municipal Income Fund's Moving Average
PIMCO California Municipal Income Fund's worth is higher than its 50-day moving average of $18.70 and above its 200-day moving average of $18.26.More news about PIMCO California Municipal Income Fund.
5. Pfizer (PFE) - Dividend Yield: 3.98%
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; a licensing agreement with Akcea Therapeutics, Inc; a strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; a clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; a material transfer and collaboration agreement with BioNTech SE; a clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; a research collaboration and license agreement with BioInvent International AB; and a multi-target drug discovery collaboration with Sosei Group Corporation. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Volume
Today's last reported volume for Pfizer is 13995800, 46.46% below its average volume of 26139100.
Pfizer's last close was $39.35, 8.66% below its 52-week high of $43.08.
News about Pfizer today
Sinovac’s vaccine found inferior to Pfizer shot in Chile study. According to today's article on Bloomberg Quint, "Sinovac Biotech Ltd.'s vaccine was less potent than Pfizer Inc.'s shot at stopping Covid-19 in Chile where the two shots were used simultaneously, the first real-world analysis comparing a China-made inoculation against an mRNA has found.", "Researchers found CoronaVac was 66% effective in preventing Covid-19 among fully vaccinated adults, versus 93% for the jab made by Pfizer and its partner BioNTech SE."
Pfizer's Sales
Pfizer's sales growth is 58.9% for the present quarter and 62.5% for the next. The company's growth estimates for the ongoing quarter and the next is 25.6% and 44.4%, respectively.
Pfizer's Revenue
Year-on-year quarterly revenue growth grew by 44.6%, now sitting on 46.41B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,Pfizer's stock is considered to be overbought (>=80).
Pfizer's Stock Yearly Top and Bottom Value
Pfizer's stock is valued at $39.04 at 12:15 EST, below its 52-week high of $43.08 and way above its 52-week low of $31.40.
Pfizer's Moving Average
Pfizer's worth is below its 50-day moving average of $39.34 and higher than its 200-day moving average of $37.28.Previous days news about Pfizer
Everest medicines announces that spero therapeutics entered into licensing agreement with Pfizer inc. for spr206 in ex-U.S. and ex-asia territories. According to Business Insider on Monday, 5 July, "Pfizer has also made a $40 million equity investment in Spero as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs.", "Under the terms of the licensing agreement, Spero has granted Pfizer the rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories. "
Israel says Pfizer vaccine is 64% effective against delta-variant infections. According to MarketWatch on Tuesday, 6 July, "Israel's health ministry said Monday the effectiveness of the COVID-19 shot developed by BioNTech SE and Pfizer Inc. is now thought to be 64% at preventing symptomatic infections in that country. "
Pfizer shot halts severe illness in Israel as delta spreads. According to Bloomberg Quint on Monday, 5 July, "The Pfizer Inc. vaccine's efficacy against mild forms of Covid-19 appeared to wane after a few weeks as the delta variant took hold in Israel, although it continued to protect against severe illness."
Could Pfizer and Moderna now face their second-worst scenario?. According to The Motley Fool on Wednesday, 7 July, "On one hand, Pfizer doesn't seem to have any worries that its vaccine is ineffective against the deadly new variant. ", "There's a major financial implication with this recent finding for Pfizer and Moderna. "
More news about Pfizer.
6. Brookfield Infrastructure Partners LP Limited Partnership Units (BIP) - Dividend Yield: 3.78%
Brookfield Infrastructure Partners L.P. owns and operates utilities, transport, energy, and data infrastructure businesses in North and South America, Europe, and the Asia Pacific. The Utilities segment operates approximately 2,000 kilometers (km) of natural gas transportation pipelines in the states of Rio de Janeiro, Sao Paulo, and Minas Gerais; approximately 2,200 km of electricity transmission lines; and approximately 6.7 million electricity and natural gas connections, as well as operates coal export terminals. The Transport segment offers transportation and storage services for freight, bulk commodities, and passengers through a network of 10,300 km of rails and 4,200 km of toll roads, as well as 37 port terminals. The Energy segment offers natural gas midstream and storage services through approximately 16,500 km of natural gas transmission pipelines; and 600 billion cubic feet of natural gas storage. This segment also provides heating and cooling services to commercial buildings and campuses, as well as serves approximately 1.6 million residential infrastructure customers. The Data Infrastructure segment offers services and critical infrastructure to the media broadcasting and telecom sectors; and data storage services and infrastructure to enterprise customers. The company was founded in 2007 and is based in Hamilton, Bermuda. Brookfield Infrastructure Partners L.P. is a subsidiary of Brookfield Asset Management Inc.
Volume
Today's last reported volume for Brookfield Infrastructure Partners LP Limited Partnership Units is 284966, 27.02% above its average volume of 224347.
Brookfield Infrastructure Partners LP Limited Partnership Units's last close was $54.25, 4.54% under its 52-week high of $56.83.
The company's growth estimates for the ongoing quarter and the next is 184% and 291.7%, respectively.Brookfield Infrastructure Partners LP Limited Partnership Units's Revenue
Year-on-year quarterly revenue growth grew by 22.2%, now sitting on 9.37B for the twelve trailing months.
Brookfield Infrastructure Partners LP Limited Partnership Units's Stock Yearly Top and Bottom Value
Brookfield Infrastructure Partners LP Limited Partnership Units's stock is valued at $56.09 at 12:15 EST, under its 52-week high of $56.83 and way above its 52-week low of $38.95.
Brookfield Infrastructure Partners LP Limited Partnership Units's Moving Average
Brookfield Infrastructure Partners LP Limited Partnership Units's worth is higher than its 50-day moving average of $54.37 and above its 200-day moving average of $53.02.More news about Brookfield Infrastructure Partners LP Limited Partnership Units.
7. iStar Financial (STAR) - Dividend Yield: 2.44%
iStar Inc. (NYSE: STAR) is focused on reinventing the ground lease sector, unlocking value for real estate owners throughout the country by providing modern, more efficient ground leases on all types of properties. As the founder, investment manager and largest shareholder of Safehold Inc. (NYSE: SAFE), the first publicly traded company to focus on modern ground leases, iStar is helping create a logical new approach to the way real estate is owned, and continues to use its historic strengths in finance and net lease to expand this unique platform. Recognized as a consistent innovator in the real estate markets, iStar specializes in identifying and scaling newly discovered opportunities and has completed more than $40 billion of transactions over the past two decades.
Volume
Today's last reported volume for iStar Financial is 644437, 17.61% below its average volume of 782207.
iStar Financial's last close was $16.84, 19.31% below its 52-week high of $20.87.
The company's growth estimates for the ongoing quarter is 475% and a drop 37.9% for the next.iStar Financial's Revenue
Year-on-year quarterly revenue growth declined by 33.7%, now sitting on 482.13M for the twelve trailing months.
iStar Financial's Stock Yearly Top and Bottom Value
iStar Financial's stock is valued at $20.68 at 12:15 EST, below its 52-week high of $20.87 and way higher than its 52-week low of $11.10.
iStar Financial's Moving Average
iStar Financial's worth is way above its 50-day moving average of $18.30 and way above its 200-day moving average of $17.23.More news about iStar Financial.